REGENXBIO Future Growth

Future criteria checks 2/6

REGENXBIO is forecast to grow earnings and revenue by 35.5% and 40.8% per annum respectively. EPS is expected to grow by 42% per annum. Return on equity is forecast to be 2.7% in 3 years.

Key information

35.5%

Earnings growth rate

42.0%

EPS growth rate

Biotechs earnings growth	24.1%
Revenue growth rate	40.8%
Future return on equity	2.7%
Analyst coverage	Good
Last updated	11 Mar 2024

Recent future growth updates

Earnings Update: REGENXBIO Inc. (NASDAQ:RGNX) Just Reported Its Yearly Results And Analysts Are Updating Their Forecasts

Mar 02

Recent updates

REGENXBIO Inc. (NASDAQ:RGNX) Not Doing Enough For Some Investors As Its Shares Slump 26%

Apr 25

Regenxbio: DMD Program Lends Additional Credibility To NAV Technology Platform

Mar 11

Analysts Just Slashed Their REGENXBIO Inc. (NASDAQ:RGNX) EPS Numbers

Mar 07

Improved Revenues Required Before REGENXBIO Inc. (NASDAQ:RGNX) Stock's 75% Jump Looks Justified

Mar 05

Earnings Update: REGENXBIO Inc. (NASDAQ:RGNX) Just Reported Its Yearly Results And Analysts Are Updating Their Forecasts

Mar 02

REGENXBIO Inc. (NASDAQ:RGNX) Analysts Just Trimmed Their Revenue Forecasts By 12%

May 11

Here's Why We're Watching REGENXBIO's (NASDAQ:RGNX) Cash Burn Situation

May 08

Analysts Are More Bearish On REGENXBIO Inc. (NASDAQ:RGNX) Than They Used To Be

Mar 05

REGENXBIO says additional phase 2 data bolsters RGX-314 for wet macular degeneration

Oct 03

Regenxbio: A Transformative Year

Sep 15

Regenxbio: Updates To Thesis, Gene Therapy Pioneer Moving To Late-Stage Development

Aug 29

Regenxbio to seek FDA's accelerated approval for Hunter Syndrome treatment, shares rise 8%

Aug 03

Regenxbio: Patience And Regular Homework Are Keys

Jul 12

REGENXBIO Inc. (NASDAQ:RGNX) Analysts Just Slashed This Year's Estimates

Jun 27

The Strong Earnings Posted By REGENXBIO (NASDAQ:RGNX) Are A Good Indication Of The Strength Of The Business

May 12

Earnings and Revenue Growth Forecasts

NasdaqGS:RGNX - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	274	-103	-1	N/A	8
12/31/2025	218	-134	-24	-149	11
12/31/2024	134	-211	-152	-202	11
12/31/2023	90	-263	-228	-218	N/A
9/30/2023	99	-261	-231	-217	N/A
6/30/2023	97	-274	-236	-218	N/A
3/31/2023	110	-270	-257	-232	N/A
12/31/2022	113	-280	-238	-207	N/A
9/30/2022	480	74	134	173	N/A
6/30/2022	484	91	128	181	N/A
3/31/2022	474	101	143	207	N/A
12/31/2021	470	128	135	219	N/A
9/30/2021	93	-212	-166	-83	N/A
6/30/2021	161	-145	-147	-77	N/A
3/31/2021	156	-121	-116	-63	N/A
12/31/2020	155	-111	-81	-54	N/A
9/30/2020	145	-91	-134	-119	N/A
6/30/2020	61	-135	-123	-112	N/A
3/31/2020	52	-103	-128	-114	N/A
12/31/2019	35	-95	-119	-108	N/A
9/30/2019	64	-64	-102	-86	N/A
6/30/2019	55	-49	-93	-77	N/A
3/31/2019	87	-37	4	17	N/A
12/31/2018	219	100	91	105	N/A
9/30/2018	180	80	84	95	N/A
6/30/2018	176	78	90	97	N/A
3/31/2018	142	53	11	18	N/A
12/31/2017	10	-73	-65	-58	N/A
9/30/2017	10	-77	N/A	-65	N/A
6/30/2017	9	-74	N/A	-59	N/A
3/31/2017	5	-74	N/A	-58	N/A
12/31/2016	5	-63	N/A	-49	N/A
9/30/2016	7	-49	N/A	-33	N/A
6/30/2016	8	-38	N/A	-29	N/A
3/31/2016	7	-32	N/A	-29	N/A
12/31/2015	8	-24	N/A	-23	N/A
9/30/2015	4	-21	N/A	-18	N/A
6/30/2015	4	-16	N/A	-13	N/A
3/31/2015	4	-8	N/A	-5	N/A
12/31/2014	6	-5	N/A	-2	N/A
12/31/2013	6	-6	N/A	-3	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: RGNX is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: RGNX is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: RGNX is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: RGNX's revenue (40.8% per year) is forecast to grow faster than the US market (8.2% per year).

High Growth Revenue: RGNX's revenue (40.8% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: RGNX's Return on Equity is forecast to be low in 3 years time (2.7%).

REGENXBIO Future Growth

Future criteria checks 2/6

Key information

Recent future growth updates

Price target increased by 7.3% to US$38.55

Consensus EPS estimates fall by 21%

Earnings Update: REGENXBIO Inc. (NASDAQ:RGNX) Just Reported Its Yearly Results And Analysts Are Updating Their Forecasts

Consensus revenue estimates fall by 16%

Price target decreased by 10% to US$36.40

Consensus EPS estimates upgraded to US$4.84 loss

Recent updates

REGENXBIO Inc. (NASDAQ:RGNX) Not Doing Enough For Some Investors As Its Shares Slump 26%

President exercised options and sold US$216k worth of stock

REGENXBIO Inc., Annual General Meeting, May 31, 2024

REGENXBIO Inc. Announces Lancet Publication of Phase I/IIa Study Evaluating ABBV-RGX-314 as a One-Time Gene Therapy for Wet AMD

President exercised options and sold US$272k worth of stock

Regenxbio: DMD Program Lends Additional Credibility To NAV Technology Platform

REGENXBIO Inc. has filed a Follow-on Equity Offering in the amount of $125 million.

REGENXBIO Inc. has completed a Follow-on Equity Offering in the amount of $140.000848 million.

Analysts Just Slashed Their REGENXBIO Inc. (NASDAQ:RGNX) EPS Numbers

REGENXBIO Inc. has completed a Follow-on Equity Offering in the amount of $140.000848 million.

Price target increased by 7.3% to US$38.55

Improved Revenues Required Before REGENXBIO Inc. (NASDAQ:RGNX) Stock's 75% Jump Looks Justified

REGENXBIO Inc. Announces New Interim Safety and Efficacy Data from Duchenne Trial

Consensus EPS estimates fall by 21%

Earnings Update: REGENXBIO Inc. (NASDAQ:RGNX) Just Reported Its Yearly Results And Analysts Are Updating Their Forecasts

New minor risk - Shareholder dilution

Full year 2023 earnings: EPS and revenues miss analyst expectations

New minor risk - Share price stability

President exercised options and sold US$195k worth of stock

REGENXBIO Inc. Announces Pivotal Trial of RGX-121 for the Treatment of MPS II Achieves Primary Endpoint

Regenxbio: Robust Data, Decent Cash, Never Ending Trials, Buying At Dips

President notifies of intention to sell stock

REGENXBIO Inc. Announces Positive Interim Data from Phase II AAVIATE® Trial of ABBV-RGX-314 for the Treatment of Wet AMD Using Suprachoroidal Delivery

Consensus revenue estimates fall by 16%

Executive VP & Chief Medical Officer notifies of intention to sell stock

President notifies of intention to sell stock

There's No Escaping REGENXBIO Inc.'s (NASDAQ:RGNX) Muted Revenues

Price target decreased by 10% to US$36.40

REGENXBIO Inc. Announces Dose Escalation in AFFINITY Duchenne®? Trial

Consensus EPS estimates upgraded to US$4.84 loss

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

We Think REGENXBIO (NASDAQ:RGNX) Needs To Drive Business Growth Carefully

REGENXBIO Inc. Presents Positive One Year Data from Phase II ALTUDE®? Trial of ABBV-RGX-314 for Treatment of Diabetic Retinopathy Using Suprachoroidal Delivery

Vitreous Retina Macula Consultants of New York Announces Participation in Wet AMD Study in Collaboration with Regenxbio

REGENXBIO Inc. Announces Additional Interim Safety Data and Initial Efficacy Data from the Phase I/II AFFINITY Duchenne Trial of RGX-202

REGENXBIO Inc. Announces Initial Clinical Data from First Pediatric CLN2 Patient Dosed with RGX-181

Consensus EPS estimates fall by 19%

Will REGENXBIO (NASDAQ:RGNX) Spend Its Cash Wisely?

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

REGENXBIO Highlights AAV Pipeline with Interim Results from Retinal and Duchenne Programs at its Virtual Investor Day on July 11, 2023

Consensus EPS estimates upgraded to US$4.26 loss

REGENXBIO Inc. (NASDAQ:RGNX) Analysts Just Trimmed Their Revenue Forecasts By 12%

Consensus revenue estimates fall by 21%

Here's Why We're Watching REGENXBIO's (NASDAQ:RGNX) Cash Burn Situation

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Analysts Are More Bearish On REGENXBIO Inc. (NASDAQ:RGNX) Than They Used To Be

Full year 2022 earnings released: US$6.50 loss per share (vs US$3.01 profit in FY 2021)

REGENXBIO Inc. Presents Interim Data from Phase II Bridging Study Evaluating the Clinical Performance of RGX-314 Using the NAVXpress™ Manufacturing Platform Process

REGENXBIO Inc. Announces Phase I/II Trial of RGX-202, a Novel Gene Therapy Candidate for Duchenne Muscular Dystrophy, Is Active and Recruiting Patients

REGENXBIO Inc. Announces Executive Promotions

Executive VP & Chief Medical Officer notifies of intention to sell stock

REGENXBIO Inc. Reports Update on Advancement of Programs for CLN2 Disease

Regenxbio Announces Completion of Dosing in the Phase I/Ii Trial of Rgx-111 for the Treatment of Severe Mps I

Price target decreased to US$44.70

Consensus revenue estimates fall by 14%

Investor sentiment deteriorated over the past week

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

REGENXBIO Inc. Presents Positive Interim Data from and the Expansion of Phase II ALTITUDE(R) Trial of Rgx-314 for the Treatment of Diabetic Retinopathy Using Suprachoroidal Delivery

REGENXBIO says additional phase 2 data bolsters RGX-314 for wet macular degeneration

Investor sentiment improved over the past week

Regenxbio: A Transformative Year

Regenxbio Inc. Announces Additional Positive Interim Data from the Phase I/Ii/Iii Campsiite™ Trial of Rgx-121 for the Treatment of Patients Up to 5 Years Old Diagnosed with Mucopolysaccharidosis Type Ii (Mps Ii), Also Known as Hunter Syndrome

Regenxbio: Updates To Thesis, Gene Therapy Pioneer Moving To Late-Stage Development

Executive VP & Chief Financial Officer notifies of intention to sell stock

Consensus forecasts updated

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

REGENXBIO Announces Intention to File a Biologics License Application Using the Accelerated Approval Pathway for RGX-121, an AAV Therapeutic for the Treatment of MPS II

Regenxbio to seek FDA's accelerated approval for Hunter Syndrome treatment, shares rise 8%

Executive VP & Chief Financial Officer recently sold US$144k worth of stock